Contact Us

Recombinant HLA-DRB (MHC II) Antibody [MSVA-478R]

Additional information

Catalog Number: 3123-RBM10
Gene:

Host:

Reactivity:

In Stock

Trial Size Available

Carrier-Free Available

download data sheet
In Stock
Catalog Number Formulation Size Price
3123-RBM10-P0
Purified Ab with BSA and Azide
20ug
$324.50
3123-RBM10-P1
Purified Ab with BSA and Azide
100ug
$654.50
Flat Rate Domestic: $95 | Orders outside the US - Contact Us for Order Information | Ships next business day
HLA-DRB1 Antibody in Numerous Tissues (IHC)

HLA-DRB1 Antibody in Numerous Tissues (IHC)

HLA class II histocompatibility antigen, DRB1 beta chain Rabbit Recombinant Monoclonal Antibody (MSVA-478R) tested on many normal and cancer tissues. The immunohistochemistry staining in these tissues aligns with the expression data in Human Protein Atlas.

  • IHC
  • Documents
  • Applications & Dilutions
  • Product Properties
  • other information

Documents

Document Name
Datasheet Download Here
Material Safety Data Sheet Download Here

Applications & Dilutions

Applications Tested Dilutions Protocol Note
Immunohistochemistry (IHC) 1:100-1:200 IHC Protocol Manual Protocol: Freshly cut sections should be used (less than 10 days between cutting and staining). Heat-induced antigen retrieval for 5 minutes in an autoclave at 121°C in pH 7.8 Target Retrieval Solution buffer. Apply the antibody at a dilution of 1:150 at 37°C for 60 minutes. Visualization of bound antibody by the EnVision Kit (Dako, Agilent) according to the manufacturer’s directions.

Product Properties

Antibody Type
Rabbit Monoclonals, Recombinant Rabbit Monoclonals
Host
Rabbit
Applications
Immunohistochemistry
Species Reactivity
Human
Clone
MSVA-478R
Isotype
IgG
Light Chain
Kappa
Cellular Localization
Cell membrane
Gene Name
HLA-DRB1
Positive Control
Liver: An at least moderate staining should be seen of sinusoids and Kupffer cells. Kidney: An at least moderate staining should be seen in glomerular capillaries.
Immunogen
Recombinant full-length human HLA-DRB1 protein
Expression System
CHO
Storage & Stability
Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
Supplied as
Ab produced in CHO cell mammalian-based expression system. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide.
Limitations
This antibody is available for research use only and is not approved for use in diagnosis.

Related Antibodies

Formalin-fixed, paraffin-embedded human Renal Cell Carcinoma stained with KSP-Cadherin Recombinant Mouse Monoclonal Antibody (rCDH16/1071).
7
  • Flow
  • IHC
  • WB

Recombinant Ksp-Cadherin (Kidney-Specific Cadherin) / CDH16 Antibody

Additional information

Catalog Number: 1014-MSM4
Reactivity:

, , , ,

Gene:

Host:

Formalin-fixed, paraffin-embedded human Renal Cell Carcinoma stained with Occludin Mouse Monoclonal Antibody (OCLN/2181).
4
  • IHC
  • WB

Occludin (Marker of Early Blood Brain Barrier Damage) Antibody

Additional information

Catalog Number: 100506658-MSM1
Reactivity:

Gene:

Host:

Formalin-fixed, paraffin-embedded Mouse Heart stained with N-Cadherin Mouse Monoclonal Antibody (CDH2/1573).
1
  • IHC

N-Cadherin / Cadherin-2 / CD325 (NCAD) Antibody

Additional information

Catalog Number: 1000-MSM3
Reactivity:

,

Gene:

Host:

Formalin-fixed, paraffin-embedded human kidney stained with MICA Mouse Recombinant Monoclonal Antibody (MICA/4443). HIER: Tris/EDTA, pH9.0, 45min. 2°C: HRP-polymer, 30min. DAB, 5min.
5
  • IHC
  • WB

MICA Antibody

Additional information

Catalog Number: 100507436-MSM3
Reactivity:

Gene:

Host:

CDH16 Antibody in Immunohistochemistry (IHC (P))
6
  • ELISA
  • IHC
  • WB

Ksp-Cadherin / CDH16 (Renal Cell Marker) Antibody

Additional information

Catalog Number: 1014-MSM5
Reactivity:

Gene:

Host:

Formalin-fixed, paraffin-embedded Human Renal Cell Carcinoma Stained with KSP-Cadherin Rabbit Polyclonal Antibody.
0
  • IHC

Ksp-Cadherin (Kidney-Specific Cadherin) / CDH16 Antibody

Additional information

Catalog Number: 1014-RBP3
Reactivity:

, ,

Gene:

Host:

Formalin-fixed, paraffin-embedded human Colon stained with Cadherin 17 / CDH17 Mouse Monoclonal Antibody (CDH17/2617).
3
  • IHC
  • WB

Cadherin 17 / LI Cadherin (Gastric Adenocarcinoma Marker) Antibody

Additional information

Catalog Number: 1015-MSM7
Reactivity:

Gene:

Host:

Formalin-fixed, paraffin-embedded human Colon stained with Cadherin 17 / CDH17 Mouse Monoclonal Antibody (CDH17/2616).
3
  • IHC
  • WB

Cadherin 17 / LI Cadherin (Gastric Adenocarcinoma Marker) Antibody

Additional information

Catalog Number: 1015-MSM6
Reactivity:

Gene:

Host:

VIEW ALL ANTIBODIES

Other Information

Functions
  • A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells (PubMed:29884618, PubMed:22327072, PubMed:27591323, PubMed:8642306, PubMed:15265931, PubMed:31495665, PubMed:16148104). Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes (PubMed:8145819). In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins (PubMed:31495665). Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance (PubMed:17182262, PubMed:23783831). The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self-peptides (PubMed:25413013). The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules (PubMed:8145819).
  • Allele DRB1*01:01: Displays an immunodominant epitope derived from Bacillus anthracis pagA/protective antigen, PA (KLPLYISNPNYKVNVYAVT), to both naive and PA-specific memory CD4-positive T cells (PubMed:22327072). Presents immunodominant HIV-1 gag peptide (FRDYVDRFYKTLRAEQASQE) on infected dendritic cells for recognition by TRAV24-TRBV2 TCR on CD4-positive T cells and controls viral load (PubMed:29884618). May present to T-helper 1 cells several HRV-16 epitopes derived from capsid proteins VP1 (PRFSLPFLSIASAYYMFYDG) and VP2 (PHQFINLRSNNSATLIVPYV), contributing to viral clearance (PubMed:27591323). Displays commonly recognized peptides derived from IAV external protein HA (PKYVKQNTLKLAT and SNGNFIAPEYAYKIVK) and from internal proteins M, NP and PB1, with M-derived epitope (GLIYNRMGAVTTEV) being the most immunogenic (PubMed:8145819, PubMed:9075930, PubMed:25413013, PubMed:32668259). Presents a self-peptide derived from COL4A3 (GWISLWKGFSF) to TCR (TRAV14 biased) on CD4-positive, FOXP3-positive regulatory T cells and mediates immune tolerance to self (PubMed:28467828). May present peptides derived from oncofetal trophoblast glycoprotein TPBG 5T4, known to be recognized by both T-helper 1 and regulatory T cells (PubMed:31619516). Displays with low affinity a self-peptide derived from MBP (VHFFKNIVTPRTP) (PubMed:9075930).
  • Allele DRB1*03:01: May present to T-helper 1 cells an HRV-16 epitope derived from capsid protein VP2 (NEKQPSDDNWLNFDGTLLGN), contributing to viral clearance (PubMed:27591323). Displays self-peptides derived from retinal SAG (NRERRGIALDGKIKHE) and thyroid TG (LSSVVVDPSIRHFDV) (PubMed:25413013). Presents viral epitopes derived from HHV-6B gH/U48 and U85 antigens to polyfunctional CD4-positive T cells with cytotoxic activity implicated in control of HHV-6B infection (PubMed:31020640). Presents several immunogenic epitopes derived from C. tetani neurotoxin tetX, playing a role in immune recognition and long-term protection (PubMed:19830726).
  • Allele DRB1*04:01: Presents an immunodominant bacterial epitope derived from M. tuberculosis esxB/culture filtrate antigen CFP-10 (EISTNIRQAGVQYSR), eliciting CD4-positive T cell effector functions such as IFNG production and cytotoxic activity (PubMed:15265931). May present to T-helper 1 cells an HRV-16 epitope derived from capsid protein VP2 (NEKQPSDDNWLNFDGTLLGN), contributing to viral clearance (PubMed:27591323). Presents tumor epitopes derived from melanoma-associated TYR antigen (QNILLSNAPLGPQFP and DYSYLQDSDPDSFQD), triggering CD4-positive T cell effector functions such as GMCSF production (PubMed:8642306). Displays preferentially citrullinated self-peptides derived from VIM (GVYATR/citSSAVR and SAVRAR/citSSVPGVR) and ACAN (VVLLVATEGR/ CitVRVNSAYQDK) (PubMed:24190431). Displays self-peptides derived from COL2A1 (PubMed:9354468).
  • Allele DRB1*04:02: Displays native or citrullinated self-peptides derived from VIM.
  • Allele DRB1*04:04: May present to T-helper 1 cells several HRV-16 epitopes derived from capsid proteins VP1 (HIVMQYMYVPPGAPIPTTRN) and VP2 (RGDSTITSQDVANAVVGYGV), contributing to viral clearance (PubMed:27591323). Displays preferentially citrullinated self-peptides derived from VIM (SAVRAR/citSSVPGVR) (PubMed:24190431).
  • Allele DRB1*04:05: May present to T-helper 1 cells an immunogenic epitope derived from tumor-associated antigen WT1 (KRYFKLSHLQMHSRKH), likely providing for effective antitumor immunity in a wide range of solid and hematological malignancies.
  • Allele DRB1*05:01: Presents an immunodominant HIV-1 gag peptide (FRDYVDRFYKTLRAEQASQE) on infected dendritic cells for recognition by TRAV24-TRBV2 TCR on CD4-positive T cells and controls viral load.
  • Allele DRB1*07:01: Upon EBV infection, presents latent antigen EBNA2 peptide (PRSPTVFYNIPPMPLPPSQL) to CD4-positive T cells, driving oligoclonal expansion and selection of a dominant virus-specific memory T cell subset with cytotoxic potential to directly eliminate virus-infected B cells (PubMed:31308093). May present to T-helper 1 cells several HRV-16 epitopes derived from capsid proteins VP1 (PRFSLPFLSIASAYYMFYDG) and VP2 (VPYVNAVPMDSMVRHNNWSL), contributing to viral clearance (PubMed:27591323). In the context of tumor immunesurveillance, may present to T-helper 1 cells an immunogenic epitope derived from tumor-associated antigen WT1 (MTEYKLVVVGAVGVGKSALTIQLI), likely providing for effective antitumor immunity in a wide range of solid and hematological malignancies (PubMed:22929521). In metastatic epithelial tumors, presents to intratumoral CD4-positive T cells a KRAS neoantigen (MTEYKLVVVGAVGVGKSALTIQLI) carrying G12V hotspot driver mutation and may mediate tumor regression (PubMed:30282837).
  • Allele DRB1*11:01: Displays an immunodominant HIV-1 gag peptide (FRDYVDRFYKTLRAEQASQE) on infected dendritic cells for recognition by TRAV24-TRBV2 TCR on CD4-positive T cells and controls viral load (PubMed:29884618). May present to T-helper 1 cells an HRV-16 epitope derived from capsid protein VP2 (SDRIIQITRGDSTITSQDVA), contributing to viral clearance (PubMed:27591323). Presents several immunogenic epitopes derived from C. tetani neurotoxin tetX, playing a role in immune recognition and longterm protection (PubMed:19830726). In the context of tumor immunesurveillance, may present tumor-derived neoantigens to CD4-positive T cells and trigger anti-tumor helper functions (PubMed:31495665).
  • Allele DRB1*13:01: Presents viral epitopes derived from HHV-6B antigens to polyfunctional CD4-positive T cells implicated in control of HHV-6B infection.
  • Allele DRB1*15:01: May present to T-helper 1 cells an HRV-16 epitope derived from capsid protein VP2 (SNNSATLIVPYVNAVPMDSM), contributing to viral clearance (PubMed:27591323). Displays a self-peptide derived from MBP (ENPVVHFFKNIVTPR) (PubMed:9782128, PubMed:25413013). May present to T-helper 1 cells an immunogenic epitope derived from tumor-associated antigen WT1 (KRYFKLSHLQMHSRKH), likely providing for effective antitumor immunity in a wide range of solid and hematological malignancies.
  • Allele DRB1*15:02: Displays an immunodominant HIV-1 gag peptide (FRDYVDRFYKTLRAEQASQE) on infected dendritic cells for recognition by TRAV24-TRBV2 TCR on CD4-positive T cells and controls viral load (PubMed:29884618). May present to T-helper 1 cells an immunogenic epitope derived from tumor-associated antigen WT1 (KRYFKLSHLQMHSRKH), likely providing for effective antitumor immunity in a wide range of solid and hematological malignancies (PubMed:19120973).
  • (Microbial infection) Acts as a receptor for Epstein-Barr virus on lymphocytes.
Key References
  • Norton AJ and Isaacson PG. 1987.Am. J. Pathol.128:225.
  • Hua ZX,et al.1998.Hum. Pathol.29(12):1441.
PubMed Links
Warranty
There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.
Entrez Gene ID
3123
SwissProt
P01911
Chromosome Location
6p21.3
Mol. Weight of Antigen
28kDa (beta chain)
Alternate Names
HLA class II histocompatibility antigen, DRB1 beta chain, Human leukocyte antigen DRB1, DRB1; HLA class II histocompatibility antigen, DR-1 beta chain; HLA-DR-beta 1; HLA-DRB1; human leucocyte antigen DRB1; Leucocyte antigen DR beta 1 chain; lymphocyte antigen DRB1; major histocompatibility complex, class II, DR beta 1; MHC class II HLA-DR beta 1 chain; MHC class II HLA-DR-beta cell surface glycoprotein

Summary

This MAb reacts with a 28kDa chain of HLA-DRB1 antigen, a member of MHC class II molecules. Â �It does not cross react with HLA-DP and HLA-DQ. The L243 antibody recognizes a different epitope than the LN3 monoclonal antibody, and these antibodies do not cross-block binding to each other’s respective epitopes. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36kDa alpha (heavy) chain and a 28kDa beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. It is an excellent histiocytic marker in paraffin sections producing intense staining. True histiocytic neoplasms are similarly positive. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.

Worry-Free Guarantee

Should a NeoBiotechnologies antibody not meet the experimental expectations outlined on our website or datasheet, please contact our Technical Support. We unconditionally guarantee our product.

Learn More

Need Technical Help?

Our team of scientists are ready to help you with expert recommendations or technical assistance related to applications or product use.

CONTACT US

Follow Us on LinkedIn

NeoBiotechnologies develops and manufactures highly specific, validated monoclonal antibodies for cancer research and diagnostics.

Phone

Whatsapp

Quick Links

Information

© 2026 NeoBiotechnologies.  All Rights Reserved.

Terms and Conditions Privacy Policy
Contact Us